PiaSky (Crovalimab-Akkz) for PNH

Overview
PiaSky is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and children 13 years and older who weigh at least 40 kilograms (around 88 pounds). PiaSky is also known by its drug name, crovalimab-akkz.

PiaSky is a biologic medication that works by inhibiting the complement protein C5, which is involved in the destruction of red blood cells in PNH. By blocking C5, PiaSky helps reduce hemolysis (the breakdown of red blood cells) and its associated symptoms.

How do I take it?
Prescribing information states that PiaSky is administered initially with a loading dose by intravenous infusion, followed by four additional loading doses via subcutaneous (under the skin) injection. After these initial doses, a maintenance dose is given every four weeks through subcutaneous injection. Dosing is based on the recipient’s body weight. It is important to follow the exact dosing schedule prescribed by a health care provider.

Side effects
Common side effects of PiaSky include infusion-related reactions, respiratory tract infections, viral infections, and type 3 hypersensitivity reactions (immune complex-mediated reactions).

Rare but serious side effects may include serious Neisseria meningococcal infections, which can be life-threatening, even in individuals who have been vaccinated. Other serious infections, particularly those caused by encapsulated bacteria, can also occur. Additionally, infusion- and injection-related reactions may require medical management. Serious hypersensitivity reactions (severe allergic reactions) to crovalimab or any of the substances used in its formulation can occur.

For more information about this treatment, visit:

PiaSky (Crovalimab-Akkz) Injection, for Intravenous or Subcutaneous Use — U.S. Food and Drug Administration

PiaSky FDA Approval History — Drugs.com